Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events | Zendy

Marc S. Sabatine | Zendy; Robert P. Giugliano | Zendy; Stephen D. Wiviott | Zendy; Frederick J. Raal | Zendy; Dirk Blom | Zendy; Jennifer G. Robinson | Zendy; Christie M. Ballantyne | Zendy; Ransi Somaratne | Zendy; Jason C. Legg | Zendy; Scott M. Wasserman | Zendy; Robert C. Scott | Zendy; Michael J. Koren | Zendy; Evan A. Stein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Author(s) -

Marc S. Sabatine,

Robert P. Giugliano,

Stephen D. Wiviott,

Frederick J. Raal,

Dirk Blom,

Jennifer G. Robinson,

Christie M. Ballantyne,

Ransi Somaratne,

Jason C. Legg,

Scott M. Wasserman,

Robert C. Scott,

Michael J. Koren,

Evan A. Stein

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1500858

Subject(s) - evolocumab , pcsk9 , kexin , proprotein convertase , medicine , monoclonal antibody , subtilisin , monoclonal , alirocumab , endocrinology , cholesterol , lipoprotein , antibody , ldl receptor , biochemistry , immunology , biology , enzyme , apolipoprotein a1

Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-term studies. We conducted two extension studies to obtain longer-term data.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research